Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions

References

• Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–290.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56(2):87–96.
   PubMedGoogle Scholar
• Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–1832.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Harabuchi Y, Kishibe K, et al. The diagnostic criteria 2015 of otitis media with ANCA associated vasculitis (OMAAV) and the commentary. Otol Jpn. 2016;26:37–39.
   Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–594.
   PubMed Web of Science ®Google Scholar
• Kahn J-E, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267–270.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan otological society. Auris Nasus Larynx. 2020. in press.
   Web of Science ®Google Scholar
• McCaffrey TV, McDonald TJ, Facer GW, et al. Otologic manifestations of Wegener’s granulomatosis. Otolaryngol Head Neck Surg (1979). 1980;88(5):586–593.
   Web of Science ®Google Scholar
• Illum P, Thorling K. Otological manifestations of Wegener’s granulomatosis. Laryngoscope. 1982;92:801–804.
   Web of Science ®Google Scholar
• McDonald TJ, DeRemee RA. Wegener’s granulomatosis. Laryngoscope. 1983;93:220–231.
   PubMed Web of Science ®Google Scholar
• Kempf HG. Ear involvement in Wegener’s granulomatosis. Clin Otolaryngol Allied Sci. 1989;14(5):451–456.
   PubMed Web of Science ®Google Scholar
• Takagi D, Nakamaru Y, Maguchi S, et al. Otologic manifestation of Wegener’s granulomatosis. Laryngoscope. 2002;112:1684–1690.
   PubMed Web of Science ®Google Scholar
• Wierzbicka M, Szyfter W, Puszczewicz M, et al. Otologic symptoms as initial manifestation of Wegener granulomatosis: diagnostic dilemma. Otol Neurotol. 2011;32(6):996–1000.
   Web of Science ®Google Scholar
• Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126(5):503–509.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Noguchi Y, Ito T, et al. [Otologic manifestations in patients with ANCA associated vasculitis-comparative analysis among microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis]. Nihon Jibiinkoka Gakkai Kaiho. 2016;119(2):110–117.
   Google Scholar
• Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol. 2017;27(1):87–94.
   PubMed Web of Science ®Google Scholar
• Suzaki I, Kimura Y, Tanaka A, et al. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab. Auris Nasus Larynx. 2019;46(1):141–146.
   Web of Science ®Google Scholar
• Iino Y, Takahashi E, Ida S, et al. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx. 2019;46(2):196–203.
   PubMed Web of Science ®Google Scholar
• Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10(8):474–483.
   Web of Science ®Google Scholar
• Praveen A, Weller P. Eosinophils and disease pathogenesis. Semin Hematol. 2012;49(2):113–119.
   Web of Science ®Google Scholar
• Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax. 1999;54(9):771–778.
   PubMed Web of Science ®Google Scholar
• Baruch-Morgenstern NB, Shik D, Moshkovits I, et al. Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil development. Nat Immunol. 2014;15(1):36–44.
   Web of Science ®Google Scholar
• Fulkerson PC, Schollaert KL, Bouffi C, et al. IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation. J Immunol. 2014;193(8):4043–4052.
   PubMed Web of Science ®Google Scholar
• Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430–436.
   Web of Science ®Google Scholar
• Komai T, Harada H, Takahashi H, et al. Reduction of myeloperoxidase-antineutrophil cytoplasmic antibody by mepolizumab in eosinophilic granulomatosis with polyangiitis. J Clin Rheumatol. 2020.
   Web of Science ®Google Scholar